3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
6
Phase 2
5
Phase 1
3
Phase 1/2
2
Status
Recruiting
4
Not yet recruiting
2
Active not recruiting
2
Completed
1
Sponsor Class
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Triple Negative Breast Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Breast Neoplasms
1
Interventions
pembrolizumab
70
Nivolumab
36
Cyclophosphamide
34
Carboplatin
28
Dexamethasone
23
Specimen Handling
22
Paclitaxel
22
Lenalidomide
22
durvalumab
19
Radiotherapy
19
Gemcitabine
19
venetoclax
18
Magnetic Resonance Spectroscopy
18
Doxorubicin
17
Rituximab
16
fludarabine
15
Ipilimumab
15
Bevacizumab
15
Cisplatin
14
Biopsy
14
atezolizumab
13
Etoposide
13
Vincristine
12
Pemetrexed
12
belantamab mafodotin
11
Docetaxel
11
Calcium Dobesilate
11
Azacitidine
11
olaparib
10
Oxaliplatin
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Active not recruiting
×
capivasertib
×
Clear all
NCT03742102
2026-04-24
BEGONIA
AstraZeneca
Phase 1/2
Active not recruiting
243 enrolled
13 charts
NCT01992952
2025-11-26
FAKTION
Velindre NHS Trust
Phase 1/2
Active not recruiting
149 enrolled